Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Efficiency of randomised clinical trials of acute respiratory distress syndrome (ARDS) depends on the fraction of deaths attributable to ARDS (AFARDS) to which interventions are targeted. Estimates of AFARDS in subpopulations of ARDS could improve design of ARDS trials.
METHODS: We performed a matched case-control study using the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE cohort. Primary outcome was intensive care unit mortality. We used nearest neighbour propensity score matching without replacement to match ARDS to non-ARDS populations. We derived two separate AFARDS estimates by matching patients with ARDS to patients with non-acute hypoxaemic respiratory failure (non-AHRF) and to patients with AHRF with unilateral infiltrates only (AHRF-UL). We also estimated AFARDS in subgroups based on severity of hypoxaemia, number of lung quadrants involved and hyperinflammatory versus hypoinflammatory phenotypes. Additionally, we derived AFAHRF estimates by matching patients with AHRF to non-AHRF controls, and AFAHRF-UL estimates by matching patients with AHRF-UL to non-AHRF controls.
RESULTS: Estimated AFARDS was 20.9% (95% CI 10.5% to 31.4%) when compared with AHRF-UL controls and 38.0% (95% CI 34.4% to 41.6%) compared with non-AHRF controls. Within subgroups, estimates for AFARDS compared with AHRF-UL controls were highest in patients with severe hypoxaemia (41.1% (95% CI 25.2% to 57.1%)), in those with four quadrant involvement on chest radiography (28.9% (95% CI 13.4% to 44.3%)) and in the hyperinflammatory subphenotype (26.8% (95% CI 6.9% to 46.7%)). Estimated AFAHRF was 33.8% (95% CI 30.5% to 37.1%) compared with non-AHRF controls. Estimated AFAHRF-UL was 21.3% (95% CI 312.8% to 29.7%) compared with non-AHRF controls.
CONCLUSIONS: Overall AFARDS mean values were between 20.9% and 38.0%, with higher AFARDS seen with severe hypoxaemia, four quadrant involvement on chest radiography and hyperinflammatory ARDS.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Thorax - 78(2023), 10 vom: 01. Okt., Seite 990-1003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saha, Rohit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 14.02.2024 published: Print-Electronic CommentIn: Thorax. 2023 Oct;78(10):955-956. - PMID 37495366 Citation Status MEDLINE |
|---|
| doi: |
10.1136/thorax-2023-220262 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359953751 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359953751 | ||
| 003 | DE-627 | ||
| 005 | 20240214232738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/thorax-2023-220262 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM359953751 | ||
| 035 | |a (NLM)37495364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saha, Rohit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Thorax. 2023 Oct;78(10):955-956. - PMID 37495366 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Efficiency of randomised clinical trials of acute respiratory distress syndrome (ARDS) depends on the fraction of deaths attributable to ARDS (AFARDS) to which interventions are targeted. Estimates of AFARDS in subpopulations of ARDS could improve design of ARDS trials | ||
| 520 | |a METHODS: We performed a matched case-control study using the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE cohort. Primary outcome was intensive care unit mortality. We used nearest neighbour propensity score matching without replacement to match ARDS to non-ARDS populations. We derived two separate AFARDS estimates by matching patients with ARDS to patients with non-acute hypoxaemic respiratory failure (non-AHRF) and to patients with AHRF with unilateral infiltrates only (AHRF-UL). We also estimated AFARDS in subgroups based on severity of hypoxaemia, number of lung quadrants involved and hyperinflammatory versus hypoinflammatory phenotypes. Additionally, we derived AFAHRF estimates by matching patients with AHRF to non-AHRF controls, and AFAHRF-UL estimates by matching patients with AHRF-UL to non-AHRF controls | ||
| 520 | |a RESULTS: Estimated AFARDS was 20.9% (95% CI 10.5% to 31.4%) when compared with AHRF-UL controls and 38.0% (95% CI 34.4% to 41.6%) compared with non-AHRF controls. Within subgroups, estimates for AFARDS compared with AHRF-UL controls were highest in patients with severe hypoxaemia (41.1% (95% CI 25.2% to 57.1%)), in those with four quadrant involvement on chest radiography (28.9% (95% CI 13.4% to 44.3%)) and in the hyperinflammatory subphenotype (26.8% (95% CI 6.9% to 46.7%)). Estimated AFAHRF was 33.8% (95% CI 30.5% to 37.1%) compared with non-AHRF controls. Estimated AFAHRF-UL was 21.3% (95% CI 312.8% to 29.7%) compared with non-AHRF controls | ||
| 520 | |a CONCLUSIONS: Overall AFARDS mean values were between 20.9% and 38.0%, with higher AFARDS seen with severe hypoxaemia, four quadrant involvement on chest radiography and hyperinflammatory ARDS | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a clinical epidemiology | |
| 700 | 1 | |a Pham, Tài |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Pratik |e verfasserin |4 aut | |
| 700 | 1 | |a Maddali, Manoj V |e verfasserin |4 aut | |
| 700 | 1 | |a Bellani, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Eddy |e verfasserin |4 aut | |
| 700 | 1 | |a Summers, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Douiri, Abdel |e verfasserin |4 aut | |
| 700 | 1 | |a Rubenfeld, Gordon D |e verfasserin |4 aut | |
| 700 | 1 | |a Calfee, Carolyn S |e verfasserin |4 aut | |
| 700 | 1 | |a Laffey, John Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Daniel Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar-Hari, Manu |e verfasserin |4 aut | |
| 700 | 0 | |a LUNG-SAFE investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Pesenti, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Laffey, John G |e investigator |4 oth | |
| 700 | 1 | |a Brochard, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Esteban, Andres |e investigator |4 oth | |
| 700 | 1 | |a Gattinoni, Luciano |e investigator |4 oth | |
| 700 | 1 | |a Haren, Frank van |e investigator |4 oth | |
| 700 | 1 | |a Larsson, Anders |e investigator |4 oth | |
| 700 | 1 | |a McAuley, Daniel F |e investigator |4 oth | |
| 700 | 1 | |a Ranieri, Marco |e investigator |4 oth | |
| 700 | 1 | |a Rubenfeld, Gordon |e investigator |4 oth | |
| 700 | 1 | |a Taylor Thompson, Boyd |e investigator |4 oth | |
| 700 | 1 | |a Wrigge, Hermann |e investigator |4 oth | |
| 700 | 1 | |a Slutsky, Arthur S |e investigator |4 oth | |
| 700 | 1 | |a Laffey, John G |e investigator |4 oth | |
| 700 | 1 | |a Giacomo, Bellani |e investigator |4 oth | |
| 700 | 1 | |a Pham, Tài |e investigator |4 oth | |
| 700 | 1 | |a Fan, Eddy |e investigator |4 oth | |
| 700 | 1 | |a Rios, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Sottiaux, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Depuydt, Pieter |e investigator |4 oth | |
| 700 | 1 | |a Lora, Fredy S |e investigator |4 oth | |
| 700 | 1 | |a Azevedo, Luciano Cesar |e investigator |4 oth | |
| 700 | 1 | |a Fan, Eddy |e investigator |4 oth | |
| 700 | 1 | |a Bugedo, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Qiu, Haibo |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Marcos |e investigator |4 oth | |
| 700 | 1 | |a Silesky, Juan |e investigator |4 oth | |
| 700 | 1 | |a Cerny, Vladimir |e investigator |4 oth | |
| 700 | 1 | |a Nielsen, Jonas |e investigator |4 oth | |
| 700 | 1 | |a Jibaja, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Pham, Tài |e investigator |4 oth | |
| 700 | 1 | |a Wrigge, Hermann |e investigator |4 oth | |
| 700 | 1 | |a Matamis, Dimitrios |e investigator |4 oth | |
| 700 | 1 | |a Ranero, Jorge Luis |e investigator |4 oth | |
| 700 | 1 | |a Amin, Pravin |e investigator |4 oth | |
| 700 | 1 | |a Hashemian, Seyed Mohammad |e investigator |4 oth | |
| 700 | 1 | |a Clarkson, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Bellani, Giacomo |e investigator |4 oth | |
| 700 | 1 | |a Kurahashi, Kiyoyasu |e investigator |4 oth | |
| 700 | 1 | |a Villagomez, Asisclo |e investigator |4 oth | |
| 700 | 1 | |a Zeggwagh, Amine Ali |e investigator |4 oth | |
| 700 | 1 | |a Heunks, Leo M |e investigator |4 oth | |
| 700 | 1 | |a Laake, Jon Henrik |e investigator |4 oth | |
| 700 | 1 | |a Palo, Jose Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Fernandes, Antero do Vale |e investigator |4 oth | |
| 700 | 1 | |a Sandesc, Dorel |e investigator |4 oth | |
| 700 | 1 | |a Arabi, Yaasen |e investigator |4 oth | |
| 700 | 1 | |a Bumbasierevic, Vesna |e investigator |4 oth | |
| 700 | 1 | |a Nin, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Lorente, Jose A |e investigator |4 oth | |
| 700 | 1 | |a Larsson, Anders |e investigator |4 oth | |
| 700 | 1 | |a Piquilloud, Lise |e investigator |4 oth | |
| 700 | 1 | |a Abroug, Fekri |e investigator |4 oth | |
| 700 | 1 | |a McAuley, Daniel F |e investigator |4 oth | |
| 700 | 1 | |a McNamee, Lia |e investigator |4 oth | |
| 700 | 1 | |a Hurtado, Javier |e investigator |4 oth | |
| 700 | 1 | |a Bajwa, Ednan |e investigator |4 oth | |
| 700 | 1 | |a Démpaire, Gabriel |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Thorax |d 1946 |g 78(2023), 10 vom: 01. Okt., Seite 990-1003 |w (DE-627)NLM00010387X |x 1468-3296 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:990-1003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/thorax-2023-220262 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 10 |b 01 |c 10 |h 990-1003 | ||